Company news from the 04/28/06 News Brief

Share this article:
Cytogen Corporation and Savient Pharmaceuticals reached a distribution agreement granting Cytogen exclusive marketing rights for Soltamox (tamoxifen citrate) in the US. Financial terms of the agreement were not disclosed. Soltamox, a cytostatic estrogen receptor antagonist, is the first oral liquid hormonal therapy approved in the US. It is indicated for the treatment of breast cancer in adjuvant and metastatic settings and to reduce the risk of breast cancer in women with ductal carcinoma in situ (DCIS) or with high risk of breast cancer.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions